Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) shot up 1.9% during trading on Tuesday . The stock traded as high as $3.75 and last traded at $2.70. 354 shares traded hands during trading, a decline of 98% from the average session volume of 14,552 shares. The stock had previously closed at $2.65.
Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of AzurRx BioPharma in a research report on Tuesday.
Several institutional investors and hedge funds have recently modified their holdings of the stock. 683 Capital Management LLC purchased a new stake in shares of AzurRx BioPharma during the second quarter worth approximately $1,284,000. Ardsley Advisory Partners increased its position in shares of AzurRx BioPharma by 66.3% during the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock worth $440,000 after purchasing an additional 54,697 shares in the last quarter. Opaleye Management Inc. purchased a new stake in AzurRx BioPharma in the 2nd quarter valued at $417,000. Gilder Gagnon Howe & Co. LLC purchased a new stake in AzurRx BioPharma in the 2nd quarter valued at $1,782,000. Finally, Parsons Capital Management Inc. RI grew its holdings in AzurRx BioPharma by 20.3% in the 1st quarter. Parsons Capital Management Inc. RI now owns 329,515 shares of the company’s stock valued at $1,035,000 after buying an additional 55,540 shares in the last quarter. Hedge funds and other institutional investors own 18.61% of the company’s stock.
About AzurRx BioPharma (NASDAQ:AZRX)
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.